Mark D Wilkie1, Helen M Fraser2, Hemal Raja3. 1. Department of Otorhinolaryngology - Head and Neck Surgery, Warrington and Halton Hospitals NHS Foundation Trust, Lovely Lane, Warrington, WA5 1QG, UK. mdwilkie@doctors.org.uk. 2. Department of Speech and Language Therapy, Bridgewater Community Healthcare NHS Foundation Trust, Lister Road, Runcorn, WA7 1TW, UK. 3. Department of Otorhinolaryngology - Head and Neck Surgery, Warrington and Halton Hospitals NHS Foundation Trust, Lovely Lane, Warrington, WA5 1QG, UK.
Abstract
OBJECTIVES: Management of laryngopharyngeal reflux (LPR) typically comprises alginates and proton pump inhibitors (PPIs) alone or in combination, yet evidence to support any particular treatment regimen is lacking. We sought to evaluate the efficacy of Gaviscon® Advance alone versus co-prescription with a PPI in treating LPR. METHODS: One hundred consecutive LPR patients with a reflux symptom index (RSI) score > 10 attending our joint voice clinic (JVC) were studied prospectively. All were treated with Gaviscon® Advance four times daily. If patients had been started on a PPI prior to their JVC attendance, this was optimised to a twice-daily dosing regimen and continued. RSI scores were recorded at first attendance and 3 months post-treatment via postal questionnaire. Scores were analysed using t tests and Levene's test for equality of variances. RESULTS: Follow-up RSI scores were returned by 72 patients, 39 of whom were treated with Gaviscon® Advance only (group A) and 33 with Gaviscon® Advance + PPI (group B). Mean pre-treatment RSI scores were similar between groups [group A: 19.2, 95% confidence interval (CI) ± 2.4; group B: 21.3, 95% CI ± 3.2 (p = 0.65)]. No significant differences were observed with respect to 3-month post-treatment RSI scores [group A: 9.9, 95% CI ± 2.8; group B: 12.6, 95% CI ± 4.2 (p = 0.82)] and change in RSI scores [group A: 9.3, 95% CI ± 3.0; group B: 8.7, 95% CI ± 2.9 [p = 0.75]). CONCLUSIONS: Gaviscon® Advance alone is effective in treating symptoms of LPR, while co-prescription with a high-dose PPI offers no additional benefit.
OBJECTIVES: Management of laryngopharyngeal reflux (LPR) typically comprises alginates and proton pump inhibitors (PPIs) alone or in combination, yet evidence to support any particular treatment regimen is lacking. We sought to evaluate the efficacy of Gaviscon® Advance alone versus co-prescription with a PPI in treating LPR. METHODS: One hundred consecutive LPR patients with a reflux symptom index (RSI) score > 10 attending our joint voice clinic (JVC) were studied prospectively. All were treated with Gaviscon® Advance four times daily. If patients had been started on a PPI prior to their JVC attendance, this was optimised to a twice-daily dosing regimen and continued. RSI scores were recorded at first attendance and 3 months post-treatment via postal questionnaire. Scores were analysed using t tests and Levene's test for equality of variances. RESULTS: Follow-up RSI scores were returned by 72 patients, 39 of whom were treated with Gaviscon® Advance only (group A) and 33 with Gaviscon® Advance + PPI (group B). Mean pre-treatment RSI scores were similar between groups [group A: 19.2, 95% confidence interval (CI) ± 2.4; group B: 21.3, 95% CI ± 3.2 (p = 0.65)]. No significant differences were observed with respect to 3-month post-treatment RSI scores [group A: 9.9, 95% CI ± 2.8; group B: 12.6, 95% CI ± 4.2 (p = 0.82)] and change in RSI scores [group A: 9.3, 95% CI ± 3.0; group B: 8.7, 95% CI ± 2.9 [p = 0.75]). CONCLUSIONS:Gaviscon® Advance alone is effective in treating symptoms of LPR, while co-prescription with a high-dose PPI offers no additional benefit.
Entities:
Keywords:
Alginates/administration and dosage; Drug combinations; Gastroesophageal reflux/drug therapy; Laryngitis/drug therapy; Laryngopharyngeal reflux/drug therapy; Proton pump inhibitors/therapeutic use; Treatment outcome
Authors: P D Karkos; J Benton; S C Leong; A Karkanevatos; K Badran; V R Srinivasan; R H Temple; W J Issing Journal: Eur Arch Otorhinolaryngol Date: 2007-02-14 Impact factor: 2.503
Authors: Woosuk Park; Douglas M Hicks; Farah Khandwala; Joel E Richter; Tom I Abelson; Claudio Milstein; Michael F Vaezi Journal: Laryngoscope Date: 2005-07 Impact factor: 3.325
Authors: Serhat Bor; İsmail Hakkı Kalkan; Altay Çelebi; Dinç Dinçer; Filiz Akyüz; Peter Dettmar; Hasan Özen Journal: Turk J Gastroenterol Date: 2019-09 Impact factor: 1.852
Authors: Amanda J Krause; Erin H Walsh; Philip A Weissbrod; Tiffany H Taft; Rena Yadlapati Journal: Ann N Y Acad Sci Date: 2021-12-17 Impact factor: 6.499
Authors: Jerome R Lechien; Francois Mouawad; Maria R Barillari; Andrea Nacci; Seyyedeh Maryam Khoddami; Necati Enver; Sampath Kumar Raghunandhan; Christian Calvo-Henriquez; Young-Gyu Eun; Sven Saussez Journal: World J Clin Cases Date: 2019-10-06 Impact factor: 1.337